Samsung Bioepis announced on March 10 the clinical results of SB5, a biosimilar to the blockbuster drug Humira, at the American Academy of Dermatology (AAD) Annual Meeting held in San Diego, California, in the U.S. on Feb. 8 (local time). This study aimed to verify whether SB5 can be interchangeably
Celltrion’s biosimilar products for the treatment of autoimmune diseases have successively won bids in major European countries.According to Celltrion on Jan. 12, Yuflyma (active ingredient: adalimumab) has successfully won a government bid in Italy. Yuflyma was awarded in the adalimumab government
On Dec. 28, the integrated company Celltrion will be officially launched. Celltrion is taking steps to leap into a global big pharmaceutical firm by merging with Celltrion Healthcare, which is responsible for global distribution.Celltrion and Celltrion Healthcare announced on Dec. 27 that they are i
Celltrion revealed on Dec. 26 that its biosimilar for autoimmune diseases, Yuflyma (CT-P17), has demonstrated equivalence and safety compared to the original drug, Humira.Developed by the American company AbbVie, Humira recorded sales of approximately US$21 brillion last year, making it the world’s
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Celltrion Healthcare posted sound 3Q23 earnings, when considering purchase price settlements. Defying market concerns, the company showed a relative return of 15%p following its merger disclosure on
Celltrion announced on Oct. 4 that it had obtained additional approval from the U.S. Food and Drug Administration (FDA) for 80mg/0.8mL and 20mg/0.2mL (hereinafter referred to as 80mg and 20mg) dosages of its Humira (active ingredient: adalimumab) biosimilar, Yuflyma (development code: CT-P17), on Se
Companies investing in biopharmaceutical-related technologies and production facilities will now be eligible for a maximum tax deduction of 35 percent.On July 27, the Ministry of Economy and Finance held the 56th session of the Tax System Advancement Review Committee presided over by Deputy Prime Mi
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Truxima’s US market share reached its highest level in 1Q23, but the drug’s quarterly price drop was also the largest in the past three years. We expect earnings growth to centere on Remsima SC in 2H
Samsung Bioepis' Humira biosimilar Hadlima (sold by Organon) has successfully been listed in the formulary recommendations list of U.S. Pharmacy Benefit Management (PBM) company Prime Therapeutics.On July 12 (local time), Prime Therapeutics announced its formulary recommendations list for Humira
On July 1 (local time), the U.S. Humira biosimilar market, worth 24 trillion won a year, opened. In the first week alone, six Korean and foreign companies plan to launch their products.According to sources in the biotech industry on July 2, Samsung Bioepis launched Hadlima, a Humira biosimilar, in t
Celltrion announced on June 5 that it had signed a contract with Rani Therapeutics, a biotech company based in San Jose, California, to develop an oral version of adalimumab (development name: RT-105).Earlier this year in January, Celltrion had signed a new drug development contract for the oral ver
The author is an analyst for Shinhan Securities. He can be reached at jaewonjeong@shinhan.com -- Ed.Pharmaceutical/bio sector to rebound in 2H23 on favorable macro conditions and progress in new drug pipelinesPharmaceutical/bio stocks have fallen out of investors’ favor with valuations declining on
The author is an analysts of NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.At Celltrion Healthcare, 1Q23 OP should arrive in line with consensus at W63.6bn. Significant sales growth was confirmed for all major items in US prescription data for March. Although one-off cost i
Samsung Bioepis's biosimilar Renflexis, SK Biopharmaceuticals' epilepsy drug Xcopri, and Daewoong Pharmaceutical's botulinum toxin Nabota, are expected to exceed US$200 million in U.S. sales this year.The Renflexis sales added up to US$196 million last year. According to industry sources
The author is an analyst of KB Securities. He can be reached at kimtaehee@kbfg.com. -- Ed.Top pick for Pharmaceuticals & Biotechnology We maintain BUY and TP of KRW1,200,000 on Samsung Biologics. Our TP remains unchanged despite revisions to 2023 ERP and RFR and slight downward adjustments to earnin
The author is an analyst of Shinhan Securities. He can be reached at shawn1225@shinhan.com. – Ed. 4Q22 preview: Overall in line, profitability to fall slightly on partial operation of Plant 4Samsung Biologics is expected to have recorded sales of KRW632bn (+42.2% YoY) and operating profit of KRW260.
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. We forecast 4Q22 sales of W610.6bn and OP of W249.7bn, falling short of consensus due to won appreciation. While growth will likely remain stagnant in 2023 amid forex rate effects and costs for plant
The sale of Humira biosimilars in the United States is scheduled to start next month. This market is expected to be as huge as US$17.3 billion. More than 10 global biopharmaceutical companies are focusing on it, including Amgen, Samsung Bioepis, and Celltrion. Samsung Bioepis' biosimilar will be
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. In 2022, healthcare stocks have been performing sluggishly in the NY stock market, affected by drastic absorption of market liquidity since early-2022. Given that 10-yr discounted cash flow is the mo
The author is an analyst of KB Securities. He can be reached at kimtaehee@kbfg.com. -- Ed. Maintain BUY, target price of KRW1,200,000 We maintain BUY and TP of KRW1,200,000 on Samsung Biologics. Our investment highlights are (1) 3Q22 earnings beat, (2) secured growth drivers via the recent start of